Oxytocin (obstetric)

Oxytocin is a nine-residue posterior pituitary hormone differing from vasopressin at only two positions, which is why it retains weak V2 activity and can cause water retention. In myometrium it binds a Gq-coupled receptor, activating phospholipase C, generating inositol trisphosphate and releasing calcium from the sarcoplasmic reticulum, which triggers contraction. Myometrial oxytocin receptor density rises perhaps a hundred-fold across gestation and peaks in labour, so responsiveness is a function of gestational stage rather than dose. After delivery, sustained contraction mechanically compresses the spiral arteries of the placental bed, which is the actual haemostatic mechanism. Prolonged high-rate infusion causes receptor desensitisation, which is one reason induced labours that stall on high-dose oxytocin do not respond to simply going higher, and why hyponatraemia from the V2 cross-reactivity becomes a genuine risk on long infusions in large fluid volumes.

Targets: Oxytocin receptor, Uterine myometrium, Breast myoepithelial cells, Weak V2 vasopressin receptor activity

• · Dosed in milliunits per minute, not micrograms. Low-dose protocols start at 0.5 to 2 mU/min and increase by 1 to 2 mU/min every 30 to 60 minutes; most units cap around 20 to 30 mU/min. The endpoint is adequate contractions, not a target dose.
• · 10 units intramuscularly, or 10 to 40 units diluted in 500 to 1000 mL of crystalloid infused to control atony. Undiluted rapid intravenous bolus can cause severe hypotension and is avoided.

Work out your exact syringe units →

• commonUterine tachysystole with fetal heart rate changes— The main obstetric hazard; excessive contraction reduces placental perfusion.
• commonHypotension and reflex tachycardia— Particularly with rapid undiluted intravenous injection at caesarean.
• commonNausea and vomiting
• uncommonWater intoxication and hyponatraemia— From V2 cross-activity plus large-volume infusion over many hours; can cause seizures and coma.
• uncommonNeonatal jaundice
• rareUterine rupture— Predominantly in women with a previous caesarean scar or grand multiparity.

• Significant cephalopelvic disproportion
• Unfavourable fetal position requiring conversion before delivery, such as transverse lie
• Obstetric emergencies favouring surgical delivery
• Fetal distress where delivery is not imminent
• Hypertonic or hyperactive uterine patterns
• Any contraindication to vaginal delivery, including total placenta praevia and active genital herpes
• Elective induction, which is explicitly not a labelled indication in the US

• redundantcarbetocin — Carbetocin is the long-acting single-dose alternative for the postpartum indication.
• conflictatosiban — Atosiban is a direct oxytocin receptor antagonist.
• cautiondesmopressin — Both promote water retention; combined use around delivery increases hyponatraemia risk.

• · Continuous fetal heart rate and uterine contraction monitoring throughout infusion
• · Maternal blood pressure and pulse
• · Fluid balance and serum sodium on prolonged infusions
• · Blood loss and uterine tone after delivery

Prescription drug worldwide; on the WHO Model List of Essential Medicines.

• Pitocin FDA prescribing information (label)
• WHO recommendations for the prevention and treatment of postpartum haemorrhage (guideline)
• Cochrane review of prophylactic oxytocin in the third stage of labour (review)

The most important thing about oxytocin in obstetrics is that responsiveness is a property of the uterus rather than of the dose. Myometrial oxytocin receptor density rises perhaps a hundred-fold across gestation and peaks in labour, so the same infusion rate that does nothing at 30 weeks produces tachysystole at term. Receptor engagement is Gq-coupled: phospholipase C generates inositol trisphosphate and diacylglycerol, IP3 releases calcium from the sarcoplasmic reticulum, calcium-calmodulin activates myosin light chain kinase and the myometrium contracts, while PKC sensitises the apparatus and oxytocin simultaneously stimulates decidual prostaglandin production, which amplifies and coordinates the contraction. The haemostatic effect after delivery is purely mechanical: sustained myometrial contraction compresses the spiral arteries running through the placental bed, and that compression, not coagulation, is what stops the bleeding. Two mechanistic facts explain most clinical problems. First, receptor desensitisation: prolonged high-rate exposure downregulates and internalises the oxytocin receptor, which is why an induced labour that stalls on 20 mU/min does not respond to going higher, and why women with long oxytocin-augmented labours are paradoxically at higher risk of postpartum atony and need more uterotonic afterwards, not less. Second, the two-residue difference from vasopressin leaves weak V2 activity, so many hours of infusion in litres of hypotonic crystalloid produces genuine water intoxication, with hyponatraemia severe enough to cause maternal and neonatal seizures. Both of those are pharmacology, not misadventure.

Tachysystole is the central obstetric hazard and it is mechanistically inevitable if you titrate too fast, because the uterus takes 30 minutes to show you what a given rate does. The uterus perfuses the placenta between contractions, so excessive contraction frequency reduces fetal oxygen delivery, and the correct response is to turn the infusion down or off rather than to push through. Second, water intoxication: many hours of infusion in litres of hypotonic fluid produces hyponatraemia severe enough to cause maternal and neonatal seizures, and it is entirely preventable by concentrating the infusion and watching fluid balance. Third, undiluted rapid intravenous bolus at caesarean causing profound hypotension. Fourth, the desensitisation trap: women who have had long oxytocin-augmented labours have downregulated receptors and are at higher risk of postpartum atony, so they need more aggressive prophylaxis afterwards, not the standard dose. Fifth, uterine rupture, predominantly in women with a previous caesarean scar or grand multiparity, where oxytocin augmentation is a recognised contributing factor. Sixth, and worth naming for completeness because this site's readers will encounter it: the intranasal oxytocin literature on trust, bonding and social cognition is a different and far weaker evidence base than the obstetric one, with poor bioavailability, unclear CNS penetration and a substantial replication problem, and it should not be read across from any of this.

1. —Induction or augmentation, start — Dosed in milliunits per minute, not micrograms. Low-dose protocols start at 0.5 to 2 mU/min through a controlled infusion pump with continuous fetal monitoring.
2. —Escalation — Increase by 1 to 2 mU/min every 30 to 60 minutes. The 30 minute minimum interval is not arbitrary: the uterus takes about that long to reach steady-state response at any given rate, so increasing faster means titrating against an effect that has not yet arrived.
3. —Ceiling — Most units cap around 20 to 30 mU/min. The endpoint is adequate contractions, roughly three to five in ten minutes with good resting tone between them, not a target dose. If labour has stalled at the cap, receptor desensitisation means going higher will not help.
4. —Postpartum haemorrhage prophylaxis — 10 units intramuscularly immediately after delivery of the infant as part of active management of the third stage.
5. —Postpartum haemorrhage treatment — 10 to 40 units diluted in 500 to 1000 mL of crystalloid, infused to control atony. Never give undiluted as a rapid intravenous bolus: it causes severe hypotension.

• Oxytocin receptor on uterine myometrium — High; receptor density rises roughly a hundred-fold across gestation and peaks in labour, so functional potency is gestation-dependent rather than dose-dependent.

  Gq-phospholipase C signalling, IP3-mediated calcium release, myosin light chain kinase activation and coordinated rhythmic contraction. Desensitises and internalises with prolonged high-rate exposure.

• Oxytocin receptor on decidua — Present

  Stimulates prostaglandin F2-alpha production, amplifying and coordinating contractions. Part of why oxytocin works better once labour has begun than as a de novo initiator.

• Oxytocin receptor on breast myoepithelial cells — High

  Milk ejection reflex. Not the obstetric purpose but the reason nipple stimulation is a physiological labour augmentation.

• Vasopressin V2 receptor — Weak cross-reactivity from the two-residue difference

  Antidiuresis. Clinically irrelevant for a single intramuscular dose and clinically dangerous over a multi-hour high-volume infusion, where it causes dilutional hyponatraemia, seizures and coma.

• Vascular smooth muscle

  Direct vasodilation causing hypotension and reflex tachycardia, dose-rate dependent, which is why an undiluted rapid intravenous bolus at caesarean is avoided.

Uterine response within about a minute intravenously and 3 to 5 minutes intramuscularly, but steady-state uterine response at any given infusion rate takes about 30 minutes, which is the interval that governs safe titration. The plasma half-life of 1 to 6 minutes means the effect fades within minutes of stopping, which makes tachysystole rapidly correctable and is the main safety advantage over long-acting uterotonics. Water intoxication develops over many hours. Receptor desensitisation develops over the course of a long induction.

In active management of the third stage, oxytocin is the first-line uterotonic and everything else is escalation, not addition: ergometrine acting on alpha-adrenergic and serotonergic receptors, misoprostol as a prostaglandin E1 analogue, carboprost as a prostaglandin F2-alpha analogue. Each has its own hard contraindications, ergometrine in hypertension and pre-eclampsia, carboprost in asthma, so knowing the patient's comorbidities before the bleeding starts matters. Tranexamic acid is genuinely additive and the evidence supports giving it early in established postpartum haemorrhage. Carbetocin replaces the prophylactic oxytocin dose rather than supplementing it. Atosiban is a direct antagonist. Desmopressin around delivery adds V2 activity from a second source and compounds the water-retention risk. The interaction that gets forgotten is with the anaesthetist: rapid oxytocin at caesarean under spinal anaesthesia stacks two causes of hypotension.

Against carbetocin: carbetocin is one injection with about an hour of sustained action and no cold chain requirement in its heat-stable form, whereas oxytocin needs a bolus plus infusion and a fridge. Oxytocin is titratable and switchable off, which carbetocin is not, and that flexibility is exactly why oxytocin remains first-line for induction and augmentation where carbetocin has no role at all. Against ergometrine: cheaper and effective but far more nausea and vomiting, and contraindicated in hypertension and pre-eclampsia, which excludes much of the highest-risk population. Against misoprostol: no cold chain and oral administration, which is decisive in the most resource-limited settings, but less effective than injectable uterotonics and it causes fever and shivering. Against no active management of the third stage: this is the comparison that matters most, because prophylactic uterotonic administration substantially reduces postpartum haemorrhage and is one of the highest-value interventions in all of obstetrics.

Not a monthly drug. Oxytocin is inexpensive, generic and on the WHO Model List of Essential Medicines. The relevant cost issue globally is not price but cold chain: oxytocin degrades in heat and a meaningful fraction of supply in tropical settings is sub-potent, which is the problem heat-stable carbetocin was developed to solve.

• ?The nine-residue sequence given is the standard published human oxytocin sequence, but the Pitocin label gives only an empirical formula and a structure image, so verified is false.
• ?Volume of distribution and plasma protein binding are not stated in the label.
• ?The 0.5 hour tmax field records the time to steady-state uterine response at a given infusion rate rather than a plasma tmax, because the former is the clinically governing number.
• ?No trials are listed as verified because I did not resolve the Cochrane reviews or the WHO evidence base in this session, despite oxytocin having one of the largest trial literatures of any drug in medicine.
• ?The intranasal social-cognition literature is deliberately excluded from this record; its bioavailability, CNS penetration and replicability are all genuinely contested.

• PITOCIN (oxytocin) injection - FDA prescribing information Par Health USA, DailyMed

  Source of the 1 to 6 minute plasma half-life, its shortening in late pregnancy and lactation, the renal and hepatic clearance with minimal unchanged urinary excretion, and the extracellular fluid distribution with probable small fetal transfer.

• WHO recommendations for the prevention and treatment of postpartum haemorrhage World Health Organization, WHO Guidelines

  Further reading, not verified this session. The source for oxytocin as first-line uterotonic in active management of the third stage of labour, and the basis for its WHO Essential Medicines listing.